norethindrone acetate has been researched along with Osteoporosis, Postmenopausal in 21 studies
norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.
Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate has no effect on vascular markers or sex hormone-binding globulin." | 2.71 | Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women. ( Eviö, S; Tiitinen, A; Välimäki, M; Ylikorkala, O, 2003) |
| "Genistein treatment significantly reduced the excretion of pyridinium cross-links at 6 months (PYR = -54 +/- 10%; DPYR = -55 +/- 13%; p < 0." | 2.70 | Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. ( Altavilla, D; Cincotta, M; Corrado, F; Crisafulli, A; D'Anna, R; Frisina, N; Gaudio, A; Ientile, R; Lasco, A; Morabito, N; Pizzoleo, MA; Squadrito, F; Vergara, C, 2002) |
| " Serum CrossLaps decreased by about 50% in the levormeloxifene groups, with no dose-response effect." | 2.70 | Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. ( Alexandersen, P; Christiansen, C; Delmas, PD; Riis, BJ; Stakkestad, JA, 2001) |
| "In a blinded, prospective, dose-response pilot study of continuous estrogen-progestin replacement therapy, 77 thin, nonsmoking, white women, who were 12 to 60 months postmenopausal and had normal medical histories, were randomly assigned to receive one of five dose combinations of daily ethinyl estradiol and norethindrone acetate (20 micrograms and 1." | 2.67 | A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. ( Frenchek, B; Speroff, L; Speroff, T; Williams, SR, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Costa-Paiva, L | 1 |
| O Wender, MC | 1 |
| Machado, RB | 1 |
| Pompei, LM | 1 |
| Nahas, EA | 1 |
| Nahas-Neto, J | 1 |
| Del Debbio, SY | 1 |
| Badalotti, M | 1 |
| Cruz, AM | 1 |
| Tuppurainen, M | 1 |
| Härmä, K | 1 |
| Komulainen, M | 1 |
| Kiviniemi, V | 1 |
| Kröger, H | 1 |
| Honkanen, R | 1 |
| Alhava, E | 1 |
| Jurvelin, J | 1 |
| Saarikoski, S | 1 |
| Posaci, C | 1 |
| Altunyurt, S | 1 |
| Islekel, H | 1 |
| Saygili, U | 1 |
| Altekin, E | 1 |
| Onvural, A | 1 |
| Onvural, B | 1 |
| Jamin, C | 1 |
| Poncelet, C | 1 |
| Madelenat, P | 1 |
| Morabito, N | 1 |
| Crisafulli, A | 1 |
| Vergara, C | 1 |
| Gaudio, A | 1 |
| Lasco, A | 1 |
| Frisina, N | 1 |
| D'Anna, R | 1 |
| Corrado, F | 1 |
| Pizzoleo, MA | 1 |
| Cincotta, M | 1 |
| Altavilla, D | 1 |
| Ientile, R | 1 |
| Squadrito, F | 1 |
| Ylikorkala, O | 2 |
| Eviö, S | 2 |
| Välimäki, M | 1 |
| Tiitinen, A | 2 |
| Popp, AW | 1 |
| Bodmer, C | 1 |
| Senn, C | 1 |
| Fuchs, G | 1 |
| Kraenzlin, ME | 1 |
| Wyss, H | 1 |
| Birkhaeuser, MH | 1 |
| Lippuner, K | 1 |
| Tarkkila, L | 1 |
| Sorsa, T | 1 |
| Furuholm, J | 1 |
| Välimäki, MJ | 1 |
| Meurman, JH | 1 |
| Yüksel, H | 1 |
| Odabaşi, AR | 1 |
| Demircan, S | 1 |
| Karul, A | 1 |
| Kozaci, LD | 1 |
| Köseoğlu, K | 1 |
| Kizilkaya, K | 1 |
| Başak, O | 1 |
| Boone, RH | 1 |
| Cheung, AM | 1 |
| Girlan, LM | 1 |
| Heathcote, EJ | 1 |
| Gambacciani, M | 1 |
| Cappagli, B | 1 |
| Ciaponi, M | 1 |
| Pepe, A | 1 |
| Vacca, F | 1 |
| Genazzani, AR | 1 |
| Stevenson, JC | 1 |
| Hillard, TC | 1 |
| Lees, B | 1 |
| Whitcroft, SI | 1 |
| Ellerington, MC | 1 |
| Whitehead, MI | 1 |
| Cubrilo-Turek, M | 1 |
| Stavljenić-Rukavina, A | 1 |
| Turek, S | 1 |
| Kusec, V | 1 |
| Duraković, Z | 1 |
| Vestergaard, P | 1 |
| Hermann, AP | 1 |
| Orskov, H | 1 |
| Mosekilde, L | 1 |
| van Hoof, HJ | 1 |
| van der Mooren, MJ | 1 |
| Swinkels, LM | 1 |
| Sweep, CG | 1 |
| Merkus, JM | 1 |
| Benraad, TJ | 1 |
| Alexandersen, P | 1 |
| Riis, BJ | 1 |
| Stakkestad, JA | 1 |
| Delmas, PD | 1 |
| Christiansen, C | 1 |
| Loh, FH | 1 |
| Chen, LH | 1 |
| Yu, SL | 1 |
| Jorgensen, LN | 1 |
| Williams, SR | 1 |
| Frenchek, B | 1 |
| Speroff, T | 1 |
| Speroff, L | 1 |
| Resch, H | 2 |
| Pietschmann, P | 2 |
| Krexner, E | 1 |
| Woloszczuk, W | 1 |
| Willvonseder, R | 2 |
| Dören, M | 1 |
| Montag, M | 1 |
| Schneider, HP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Clinical Trial on the Effectts of Estradiol 2 mg + NETA 1 mg With or Without Clodronate on Bone Mineral Density and Bone Markers of Osteoporotic Postmenopausal 167 Finnish Women.[NCT00877097] | 167 participants (Actual) | Interventional | 1996-07-31 | Completed | |||
| Genistein Use in Postmenopausal Women With Metabolic Syndrome[NCT00541710] | Phase 2/Phase 3 | 120 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for norethindrone acetate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
[Tibolone].
Topics: Adult; Aged; Animals; Blood Coagulation; Breast; Cardiovascular Diseases; Controlled Clinical Trials | 2002 |
16 trials available for norethindrone acetate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Effects of ultra-low dose hormone therapy on biochemical bone turnover markers in postmenopausal women: A randomized, placebo-controlled, double-blind trial.
Topics: Alkaline Phosphatase; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Collagen Type I; D | 2022 |
Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
Topics: Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Clodronic Acid; Drug Therapy, | 2010 |
Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
Topics: Alkaline Phosphatase; Amino Acids; Bone Density; Combined Modality Therapy; Diet, Fat-Restricted; Do | 2002 |
Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; C-Reactive Protein; Double-Blind Method; | 2003 |
Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Topics: Body Mass Index; Bone Density; Endometrial Hyperplasia; Endometrium; Estradiol; Estrogen Replacement | 2006 |
Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind M | 2006 |
Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition.
Topics: Administration, Oral; Adult; Aged; Body Composition; Body Mass Index; Body Weight; Double-Blind Meth | 2006 |
Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin.
Topics: Administration, Cutaneous; Bilirubin; Bone Density; Double-Blind Method; Estradiol; Estrogen Replace | 2006 |
Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
Topics: Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Contraceptives, Oral, Synthetic; D | 2008 |
Postmenopausal bone loss: does HRT always work?
Topics: Administration, Cutaneous; Administration, Oral; Alkaline Phosphatase; Bone Density; Calcium; Creati | 1993 |
Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study.
Topics: Bone Density; Cross-Sectional Studies; Denmark; Estradiol; Estrogen Replacement Therapy; Female; Hum | 1999 |
Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.
Topics: Bone Density; Calcium; Cholesterol; Double-Blind Method; Endometrium; Estradiol; Estrogen Replacemen | 2001 |
The efficacy of two dosages of a continuous combined hormone replacement regimen.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Asian People; Cholesterol; Cholesterol, HDL; Cholesterol, L | 2002 |
A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement.
Topics: Adult; Biopsy; Bone Density; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; D | 1990 |
Estimated long-term effect of calcitonin treatment in acute osteoporotic spine fractures.
Topics: Aged; Bone and Bones; Calcitonin; Calcium; Estradiol; Female; Fractures, Spontaneous; Humans; Middle | 1989 |
[Prospective perimenopausal estrogen-progestin substitution therapies for the prevention of osteoporosis].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Estradiol; Estriol; Female; Humans; Medroxyprog | 1989 |
4 other studies available for norethindrone acetate and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
The values of urinary NTx in postmenopausal women undergoing HRT; the role of additional alendronate therapy.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Alendronate; Bone Density; Collagen; Collage | 2002 |
The usefulness of biochemical bone markers in predicting the response of hormone replacement therapy in perimenopausal cigarette smoking healthy women.
Topics: Alkaline Phosphatase; Biomarkers; Calcium; Collagen; Collagen Type I; Estradiol; Estrogen Replacemen | 1999 |
Female sex hormone replacement therapy increases serum free 1,25-dihydroxyvitamin D3: a 1-year prospective study.
Topics: Calcitriol; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Female; Humans; Midd | 1999 |
Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures.
Topics: Alkaline Phosphatase; Bone and Bones; Double-Blind Method; Drug Therapy, Combination; Estradiol; Est | 1990 |